Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.55 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14253316 | 0.98 | FAAH (0.58) | FAAHASAH1MEN1KMT2AKDM4E | |
| SCHEMBL11310187 | 0.98 | FAAH (0.58) | FAAHASAH1MEN1KMT2AKDM4E | |
| SCHEMBL968572 | 0.98 | FAAH (0.58) | FAAHASAH1MEN1KMT2AKDM4E | |
| SCHEMBL24339916 | 0.98 | FAAH (0.58) | FAAHASAH1MEN1KMT2AKDM4E | |
| SCHEMBL1004187 | 0.98 | FAAH (0.58) | FAAHASAH1MEN1KMT2AKDM4E | |
| SCHEMBL26393717 | 0.98 | FAAH (0.58) | FAAHASAH1MEN1KMT2AKDM4E | |
| SCHEMBL5410583 | 0.98 | FAAH (0.58) | FAAHASAH1MEN1KMT2AKDM4E | |
| SCHEMBL9061545 | 0.98 | FAAH (0.58) | FAAHASAH1MEN1KMT2AKDM4E | |
| SCHEMBL22067566 | 0.98 | FAAH (0.58) | FAAHASAH1MEN1KMT2AKDM4E | |
| SCHEMBL13213912 | 0.98 | FAAH (0.58) | FAAHASAH1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744791-B2 | Cosmetic composition comprising amide-based compound | NEOPHARM CO., LTD. (KR) | 2023-09-05 | — | — | US | claimed |
| US-20210283041-A1 | COSMETIC COMPOSITION COMPRISING AMIDE-BASED COMPOUND | NEOPHARM CO., LTD. (KR) | 2021-09-16 | — | — | US | claimed |
| US-11744791-B2 | Cosmetic composition comprising amide-based compound | NEOPHARM CO., LTD. (KR) | 2023-09-05 | — | — | US | disclosed |
| US-20210283041-A1 | COSMETIC COMPOSITION COMPRISING AMIDE-BASED COMPOUND | NEOPHARM CO., LTD. (KR) | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283041-A1 | COSMETIC COMPOSITION COMPRISING AMIDE-BASED COMPOUND | FABP4, PPARG, PPARA | FAAH 131/4885ASAH1 165/4885MEN1 4873/4885 |
| US-11744791-B2 | Cosmetic composition comprising amide-based compound | FABP4, PPARG, PPARA | FAAH 131/4885ASAH1 165/4885MEN1 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.